Other Pharmaceuticals - Gabon

Gabon

The Other Pharmaceuticals market in Gabon is expected to witness significant growth in the coming years.
It is projected that the revenue in this market will reach US$17.79m in 2024.
Furthermore, a steady annual growth rate of 3.17% is anticipated between 2024 and 2029, resulting in a market volume of US$20.79m by 2029.
When compared globally, it is worth noting that United States will generate the highest revenue in this market, amounting to US$260.50bn in 2024.
Gabon's pharmaceutical market is experiencing a surge in demand for alternative medicines and traditional remedies.

Key regions: China, Europe, Australia, United States, Germany

Market

Region

Region comparison

Currency

Analyst Opinion

The Other Pharmaceuticals market in Gabon has been experiencing significant growth in recent years.

Customer preferences: Gabon has a growing population with an increasing demand for healthcare services. The government has been investing in the healthcare sector, which has led to an increase in demand for pharmaceutical products. Customers in Gabon prefer high-quality pharmaceutical products that are affordable and easily accessible.

Trends in the market: The Other Pharmaceuticals market in Gabon has been growing due to the increasing demand for pharmaceutical products. The market has been expanding due to the rise in chronic diseases, such as diabetes and cancer, which require long-term medication. The market has also been growing due to the increasing awareness of the importance of preventive healthcare.

Local special circumstances: Gabon is a country located in Central Africa with a population of approximately 2.2 million people. The country has a relatively small pharmaceutical industry, which has led to a high dependence on imported pharmaceutical products. The government has been implementing policies to encourage local production of pharmaceutical products to reduce the country's dependence on imports.

Underlying macroeconomic factors: The Gabonese economy has been growing due to the country's rich natural resources, including oil, manganese, and timber. The government has been investing in infrastructure development, which has led to an increase in foreign investment. The growing economy has led to an increase in disposable income, which has contributed to the growth of the Other Pharmaceuticals market. The government's investment in the healthcare sector has also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.